US Stock Insider Trading | Fortive Pharmaceuticals Disclosed 11 Insider Transactions on February 26

2026-03-24 14:46:59

On February 26, 2026, Vertex Pharmaceuticals (VRTX) disclosed 11 insider transactions. Director Reshma Kewalramani sold 4,981 shares on February 25, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
2026-02-26	Executive	Carmen Bozic	2026-02-24	Sell	1,453	485.11	$704,900
2026-02-26	Executive	Duncan McKechnie	2026-02-25	Sell	2,410	489.00	$1,178,500
2026-02-26	Executive	Jonathan Biller	2026-02-24	Sell	1,144	485.11	$554,900
2026-02-26	Executive	Jonathan Biller	2026-02-25	Sell	945	486.35	$459,600
2026-02-26	Executive	Duncan McKechnie	2026-02-24	Sell	873	485.11	$423,500
2026-02-26	Executive	Duncan McKechnie	2026-02-25	Sell	2,500	486.35	$1,215,900
2026-02-26	Director	Reshma Kewalramani	2026-02-24	Sell	4,981	485.11	$2,416,300
2026-02-26	Director	Jeffrey M. Leiden	2026-02-24	Sell	3,547	485.11	$1,720,700
2026-02-26	Executive	Amit Sachdev	2026-02-25	Sell	1,846	486.35	$897,800
2026-02-26	Executive	Amit Sachdev	2026-02-24	Sell	1,518	485.11	$736,400

[Company Profile]

Vertex Pharmaceuticals Incorporated was founded in 1989 in Massachusetts. It is a global biotechnology company dedicated to scientific innovation, aiming to create transformative medicines for individuals with serious diseases, especially in specialized markets. The company has developed approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta-thalassemia, and acute pain. It continues to innovate and advance next-generation clinical and research projects across various serious diseases, including IgA nephropathy and type 1 diabetes.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.